While Akebia Therapeutics Inc. has overperformed by 6.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AKBA rose by 225.09%, with highs and lows ranging from $2.08 to $0.49, whereas the simple moving average jumped by 72.17% in the last 200 days.
On November 29, 2023, BTIG Research started tracking Akebia Therapeutics Inc. (NASDAQ: AKBA) recommending Buy. A report published by H.C. Wainwright on August 28, 2023, Upgraded its rating to ‘Buy’ for AKBA. Piper Sandler also Upgraded AKBA shares as ‘Overweight’, setting a target price of $4 on the company’s shares in a report dated May 31, 2023. Piper Sandler March 31, 2022d the rating to Neutral on March 31, 2022, and set its price target from $8 to $2. Needham March 31, 2022d its ‘Buy’ rating to ‘Hold’ for AKBA, as published in its report on March 31, 2022. Mizuho’s report from March 31, 2022 suggests a price prediction of $2 for AKBA shares, giving the stock a ‘Neutral’ rating. H.C. Wainwright also rated the stock as ‘Neutral’.
Analysis of Akebia Therapeutics Inc. (AKBA)
Further, the quarter-over-quarter increase in sales is 2.06%, showing a positive trend in the upcoming months.
One of the most important indicators of Akebia Therapeutics Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -554.87% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.03, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and AKBA is recording 2.75M average volume. On a monthly basis, the volatility of the stock is set at 9.72%, whereas on a weekly basis, it is put at 11.23%, with a gain of 27.65% over the past seven days. Furthermore, long-term investors anticipate a median target price of $4.33, showing growth from the present price of $2.17, which can serve as yet another indication of whether AKBA is worth investing in or should be passed over.
How Do You Analyze Akebia Therapeutics Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.05%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 18.43% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AKBA shares are owned by institutional investors to the tune of 18.43% at present.
